Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

被引：182

作者：

Avet-Loiseau, Herve ^{[1
,2
]}

Attal, Michel ^{[4
]}

Campion, Loic ^{[5
]}

Caillot, Denis ^{[6
]}

Hulin, Cyrille ^{[7
]}

Marit, Gerald ^{[8
]}

Stoppa, Anne-Marie ^{[9
]}

Voillat, Laurent ^{[10
]}

Wetterwald, Marc ^{[11
]}

Pegourie, Brigitte ^{[12
]}

Voog, Eric ^{[13
]}

Tiab, Mourad ^{[14
]}

Banos, Anne ^{[15
]}

Jaubert, Jerome ^{[16
]}

Bouscary, Didier ^{[18
]}

Macro, Margaret ^{[19
]}

Kolb, Brigitte ^{[20
]}

Traulle, Catherine ^{[21
]}

Mathiot, Claire ^{[17
]}

Magrangeas, Florence ^{[1
,2
]}

Minvielle, Stephane ^{[1
,2
]}

Facon, Thierry ^{[22
]}

Moreau, Philippe ^{[3
]}

机构：

[1] Ctr Hosp Univ, Inst Natl Sante & Rech Med U892, Nantes, France

[2] Univ Nantes, Nantes, France

[3] Univ Hosp Hotel Dieu, Nantes, France

[4] Ctr Hosp Univ, Toulouse, France

[5] Ctr Rene Gauducheau, St Herblain, France

[6] Ctr Hosp Univ, Dijon, France

[7] Ctr Hosp Univ, Nancy, France

[8] Ctr Hosp Univ, Bordeaux, France

[9] Inst J Paoli I Calmettes, F-13009 Marseille, France

[10] Ctr Hosp, Chalon Sur Saone, France

[11] Ctr Hosp, Dunkerque, France

[12] Ctr Hosp Univ, Grenoble, France

[13] Ctr Jean Bernard, Le Mans, France

[14] Ctr Hosp, La Roche Sur Yon, France

[15] Ctr Hosp, Bayonne, France

[16] Ctr Hosp Univ, St Etienne, France

[17] Inst Curie, Paris, France

[18] Ctr Hosp Univ Cochin, Paris, France

[19] Ctr Hosp Univ, Caen, France

[20] Ctr Hosp Univ, Reims, France

[21] Ctr Hosp Univ, Pierre Benite, France

[22] Ctr Hosp Univ, Lille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 16期

关键词：

STEM-CELL TRANSPLANTATION; IN-SITU HYBRIDIZATION; MULTIPLE-MYELOMA; INTERGROUPE FRANCOPHONE; PROGNOSTIC-FACTOR; THERAPY;

D O I：

10.1200/JCO.2011.36.5726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials. Patients and Methods A series of 520 patients was analyzed. Median follow-up was 90.5 months. To perform a comprehensive analysis of the major prognostic factors, we reanalyzed all patients for 1q gains [in addition to updating del(13), t(4; 14), and del(17p) analyses]. Results It was possible to identify a subgroup of patients (representing 20% of total patients) with an 8-year survival of 75%. These patients were defined by the absence of t(4; 14), del(17p), and 1q gain and beta(2)-microglobulin less than 5.5 mg/L. Conclusion We propose that all patients with newly diagnosed multiple myeloma be evaluated for these three chromosomal changes, not only to define high-risk patients but also to identify those with a longer life expectancy.

引用

页码：1949 / 1952

页数：4

共 12 条

[1] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[2] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[3] Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? [J].

Avet-Loiseau, Herve ;

Malard, Florent ;

Campion, Loic ;

Magrangeas, Florence ;

Sebban, Catherine ;

Lioure, Bruno ;

Decaux, Olivier ;

Lamy, Thierry ;

Legros, Laurence ;

Fuzibet, Jean-Gabriel ;

Michallet, Mauricette ;

Corront, Bernadette ;

Lenain, Pascal ;

Hulin, Cyrille ;

Mathiot, Claire ;

Attal, Michel ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Minvielle, Stephane ;

Moreau, Philippe .

BLOOD, 2011, 117 (06) :2009-2011

[4] Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences [J].

Barlogie, Bart ;

Attal, Michel ;

Crowley, John ;

van Rhee, Frits ;

Szymonifka, Jackie ;

Moreau, Philippe ;

Durie, Brian G. M. ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1209-1214

[5] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].

Chang, H ;

Qi, C ;

Yi, QL ;

Reece, D ;

Stewart, AK .

BLOOD, 2005, 105 (01) :358-360

[6] The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant [J].

Chang, H ;

Sloan, S ;

Li, D ;

Zhuang, LH ;

Yi, QL ;

Chen, CI ;

Reece, D ;

Chun, K ;

Stewart, AK .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :64-68

[7] Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma [J].

Fonseca, R. ;

Van Wier, S. A. ;

Chng, W. J. ;

Ketterling, R. ;

Lacy, M. Q. ;

Dispenzieri, A. ;

Bergsagel, P. L. ;

Rajkumar, S. V. ;

Greipp, P. R. ;

Litzow, M. R. ;

Price-Troska, T. ;

Henderson, K. J. ;

Ahmann, G. J. ;

Gertz, M. A. .

LEUKEMIA, 2006, 20 (11) :2034-2040

[8] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

[9] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Greipp, PR ;

Litzow, MR ;

Henderson, KJ ;

Van Wier, SA ;

Ahmann, GJ ;

Fonseca, R .

BLOOD, 2005, 106 (08) :2837-2840

[10] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

← 1 2 →